|
|
Volumn 509, Issue 7500, 2014, Pages 269-270
|
|
Microbiome therapy gains market traction.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
N ACETYLNEURAMINIC ACID;
PROBIOTIC AGENT;
ANIMAL;
BIOTECHNOLOGY;
CLINICAL TRIAL (TOPIC);
DIABETES MELLITUS;
DRUG EFFECT;
ECONOMICS;
HUMAN;
INTESTINE;
INVESTMENT;
METABOLISM;
MICROBIOLOGY;
MICROFLORA;
MOUSE;
MULTIPLE SCLEROSIS;
NOTE;
PHYSIOLOGY;
PREVOTELLA;
RHEUMATOID ARTHRITIS;
ULCERATIVE COLITIS;
ANIMALS;
ARTHRITIS, RHEUMATOID;
BIOTECHNOLOGY;
CLINICAL TRIALS AS TOPIC;
COLITIS, ULCERATIVE;
DIABETES MELLITUS;
HUMANS;
INTESTINES;
INVESTMENTS;
MICE;
MICROBIOTA;
MULTIPLE SCLEROSIS;
N-ACETYLNEURAMINIC ACID;
PREVOTELLA;
PROBIOTICS;
|
|
EID: 84905080906
PISSN: None
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/509269a Document Type: Note |
|
Times cited : (33)
|
|
References (0)
|
